Indivior PLC (NASDAQ:INDV) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Indivior PLC (NASDAQ:INDV) have received a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $19.60.

Several research firms have recently commented on INDV. Craig Hallum raised their price objective on shares of Indivior from $15.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 30th. Jefferies Financial Group started coverage on shares of Indivior in a report on Tuesday, July 22nd. They set a “buy” rating and a $20.00 target price on the stock. HC Wainwright assumed coverage on shares of Indivior in a research note on Wednesday, August 6th. They issued a “buy” rating and a $27.00 price target for the company. Finally, Wall Street Zen upgraded Indivior from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 21st.

Indivior Stock Performance

INDV opened at $24.15 on Friday. Indivior has a 52 week low of $7.33 and a 52 week high of $24.24. The business has a fifty day simple moving average of $17.40 and a 200-day simple moving average of $12.86.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, July 31st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.25. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%.The firm had revenue of $302.00 million for the quarter, compared to analyst estimates of $239.43 million. Indivior has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Indivior will post 1.22 EPS for the current year.

Institutional Investors Weigh In On Indivior

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Two Seas Capital LP increased its holdings in Indivior by 0.4% in the second quarter. Two Seas Capital LP now owns 11,407,795 shares of the company’s stock valued at $168,151,000 after buying an additional 41,018 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its position in shares of Indivior by 74.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company’s stock worth $110,418,000 after acquiring an additional 3,790,518 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after acquiring an additional 1,299,425 shares during the last quarter. Rubric Capital Management LP increased its holdings in shares of Indivior by 31.6% in the 2nd quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock valued at $68,499,000 after acquiring an additional 1,117,140 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Indivior by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 4,631,221 shares of the company’s stock worth $43,765,000 after acquiring an additional 71,539 shares in the last quarter. 60.33% of the stock is currently owned by institutional investors and hedge funds.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.